Clinical Trials Logo

Filter by:
NCT ID: NCT05517109 Completed - Clinical trials for Acute Ischemic Stroke

Hemodynamic in Postreperfusion Period and Functional Recovery in Acute Ischemic Stroke Patients

Start date: March 12, 2022
Phase: N/A
Study type: Interventional

The investigators are suggtesting that lower goals of systolic blood pressure after intravenous thrombolysis may reduce the risk of hemorrhagic complications and improve functional outcomes after acute ischemic stroke.

NCT ID: NCT05505097 Completed - Infections Clinical Trials

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Start date: May 4, 2022
Phase: Phase 1
Study type: Interventional

The study aimed for: 1. To study the safety of the drug Dioxidin, solution for topical and external use; 2. To determine the concentrations of the active substance of the studied drugs Dioxidin, solution for topical and external use, and Dioxidin, solution for infusion and external use in discrete time intervals; 3. To study pharmacokinetics of the drug Dioxidin, solution for topical and external application; 4. To determine the absolute bioavailability of the drug Dioxidine, solution for topical and external use.

NCT ID: NCT05498233 Completed - Pregnancy Related Clinical Trials

Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers

Start date: August 18, 2022
Phase: N/A
Study type: Interventional

The study aimed for: 1. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), in healthy volunteers in fasted conditions. 2. Comparative evaluation of the safety of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSK, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), based on the analysis of adverse events (AEs).

NCT ID: NCT05494827 Completed - Healthy Clinical Trials

The Impact of a Regular Borjomi® Consumption on an Anaerobic Performance

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

The effects of 2 weeks 1000 ml daily mineral water Borjomy® consumption of anaerobic performance and acid-base balance in comparison with purified electrolite smart-water and still drinking water.

NCT ID: NCT05492409 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura

NCT ID: NCT05492084 Completed - Clinical trials for Atherosclerosis, Coronary

Personalized Risk of Rapidly Progressive Atherosclerosis

RPA
Start date: January 1, 2019
Phase:
Study type: Observational

Š’ackground. Progressive atherosclerosis is accompanied by unfavorable clinical outcomes, study and understanding of this process, creation of risk assessment method is necessary for individualization of approaches to treatment and prevention of this condition. Purpose of the study. Creation of a mathematical model to assess the risk of accelerated atherosclerosis development, using methods of factor and correlation analysis. Patient Characteristics and Study Methods. A retrospective cohort study included 202 patients with coronary heart disease. Group 1 included patients who had had myocardial infarction or unstable angina, emergency arterial stenting, stroke, peripheral artery thrombosis, critical ischemia, and lower extremity amputation within 2 years before study inclusion. Patients in the comparison group did not have these events. The influence of each of the studied parameters on the probability of fast progressing atherosclerosis was determined by factor and correlation analysis. The prospective part of the study will include follow-up of patients from both groups for 12 months. Annual "endpoints": fatal outcome, unscheduled coronary revascularization, nonfatal myocardial infarction and stroke, hospitalization due to unstable angina pectoris, stent thrombosis, stenting/plasty of lower limb arteries.

NCT ID: NCT05491148 Completed - Clinical trials for ?hanges in the Cardiovascular System in Healthcare Workers During Work Shift

Study of the Functional State of the Body of Medical Workers in the Intensive Care Unit for Newborns

Start date: August 29, 2022
Phase:
Study type: Observational

The purpose of this work is to assess the functional state of the body of medical workers in the neonatal resuscitation and intensive care unit in the conditions of work.

NCT ID: NCT05483205 Completed - Acne, Adult Clinical Trials

Normaderm Phytosolution Global Observational Study

Start date: July 1, 2019
Phase:
Study type: Observational

The objective of this 3-month observational study was to assess, in 2827 adults, the benefit of NP alone or as adjunctive or maintenance care in mild acne, or as adjunctive care in subjects with moderate acne.

NCT ID: NCT05471310 Completed - Clinical trials for Ataxia Telangiectasia

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Start date: March 15, 2021
Phase:
Study type: Observational

Ataxia-telangiectasia (A-T) is a multisystem auto-somal recessive disorder linked to the A-T mutated gene (ATM) on chromosome 11q22-23, and characterized by progressive neural degeneration, immunodeficiency, and progressive ocular motor dysfunction. In previous studies, the quantitative description of the ocular motor deficits from clinical examination was limited to various defects in saccade and gaze control, dysmetric saccades, impairments of smooth pursuit, gaze holding, convergence, vestibular and optokinetic nystagmus slow phases, and cancellation of the vestibulo-ocular reflex. The aim of our research is to add existing findings with quantitative description of oculomotor patterns in A-T patients using videooculography (VOG).

NCT ID: NCT05470582 Completed - Influenza, Human Clinical Trials

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Start date: February 16, 2021
Phase: Phase 3
Study type: Interventional

Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the first vaccination).